Leveraging the business environment and supporting policies for developing new growth drivers in Qingdao International Academician Park, the company is involved in innovative drug development for major diseases that have unmet clinical needs. The company enjoys unique advantages, specifically in the fields of drug addiction, cerebral stroke, Alzheimer's disease, schizophrenia, major depression, and myocardial infarction.

Its experienced research and development team is exploring and developing innovative products through independent research and development and self-innovation, which are bringing therapeutic effects to patients.

The company has acquired the intellectual property rights for drug molecular entities and indications in China and the global market via purchase, authorization and other means. One of its products, PMS-001, has received a global patent; PMS-002 and PMS-003 have completed the applications for international PCT patent and are entering the national registration phase; while PMS-004 has received a regional patent authorization for the China market.

The company has constantly enhanced academic and scientific research exchanges with domestic and international scientific research institutes and universities. It has also deepened project cooperation with renowned pharmaceutical enterprises across China and the world. It has established a long-term collaborative innovation mechanism and promotes industrial development. The company is filling the gap in terms of the huge shortage in the market for drug products related to major neurological diseases and is benefiting the whole society. It is also promoting the overall development and industrial layout for the pharmaceutical industry in Shandong Province, and is driving local economic development and industrial transformation and upgrade.

Cutting-edge innovative R&D capabilities, rich drug research and development experience, accurate interpretation of pharmaceutical policies, and competent commercial operation capabilities have helped us to become trustworthy partners for global biopharmaceutical enterprises and investment institutions.